Gadi, V., Hart, L. L., Tarantino, P., Sharma, P., Sammons, S. L., Mavros, P., Kaur, M., Boualam, N., Keane, C., Sopher, G. M., Pathak, P., Rugo, H. S. (2026). (RW) post-progression outcomes following first-line (1L) ribociclib (RIB) + aromatase inhibitor (AI) versus AI alone in African American and low socio-economic status (SES) patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) in US.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1073